Elektrofi, Inc., a biopharmaceutical formulation technology company specializing in strategic partnerships to revolutionize the delivery of biologic therapies, has announced a multi-target research collaboration and license agreement with Eli Lilly and Company. This partnership aims to develop next-generation medicines that can be delivered subcutaneously, reinforcing Elektrofi's position as a global scientific technology innovator in the field of biologic delivery. They leverage their proprietary ultra-high concentration microparticle suspension technology platform.

Elektrofi, expressed the company's commitment to patient-centered care and the belief that patients should have access to life-changing therapies on their terms. The collaboration with Lilly further validates Elektrofi's expertise and capabilities, particularly in autoimmune disease, oncology, and neuroscience. The Elektrofi team eagerly anticipates collaborating with Lilly to achieve groundbreaking innovations.

Collaboration Details:

Elektrofi will receive an upfront payment of $20 million from Lilly in exchange for granting Lilly exclusive rights to three specific therapeutic targets.

Elektrofi stands to earn potential future payments exceeding $150 million for each target, subject to reaching developmental, regulatory, and sales-related milestones, as well as tiered royalties based on global net sales.

Additionally, Lilly has the option to secure up to two more therapeutic targets for extra payments.

Lilly will take on the responsibility for clinical development and commercialization of each product.

 

Source: globenewswire.com

Report Abuse